INTRODUCTION

- Toll-like receptor (TLR) pathway plays an important role in the pathogenesis of cancer.
- There are several TLR agonists that can activate immune cells and induce tumor cell death.
- Entolimod is a Toll-like receptor 5 (TLR5) agonist that has shown promising preclinical activity.

METHODS

- Patients with locally advanced, inoperable, or metastatic solid tumors were enrolled in a phase I study.
- Eligible patients included those aged 18 years or older with a Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- The clinical activity of TLR5 agonists was evaluated within the first 31 days of treatment.
- Treatment was well tolerated.

RESULTS

- Common adverse events were as follows:
  - Myalgia
  - Fatigue
  - Nausea
  - Rash
- Pharmacodynamics:
  - Cytokines were measured at baseline and after treatment.
- Pharmacokinetics:
  - Entolimod PK appears dose proportional and consistent with other TLR agonists.

CONCLUSION

- Entolimod was well tolerated.
- The clinical results corroborated pre-clinical findings and support further development.
- The safety profile suggests that entolimod can be combined with chemotherapy, targeted, or other immunotherapeutic agents.